Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 4/20 | 0.41 |
| ▸ | PIM3 | Q86V86 | 4/20 | 0.41 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.34 |
| ▸ | RAF1 | P04049 | 1/20 | 0.34 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.34 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 4/20 | 0.33 |
| ▸ | RAB9A | P51151 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16167590 | 0.85 | PIK3C3 (0.44) | PIK3C3PIM1PIM3PIM2DYRK1A | |
| SCHEMBL9107567 | 0.85 | MAPK13 (0.45) | MAPK13RAF1MAPK12MAPK11MAPK14 | |
| SCHEMBL9890572 | 0.80 | GSK3B (0.49) | MAPK14 | |
| SCHEMBL626224 | 0.80 | JAK2 (0.42) | MAPK14NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL9108071 | 0.78 | MAPK14 (0.46) | MAPK14RAB9ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL9104647 | 0.78 | CDC7 (0.42) | DYRK1AMAPK14NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9110056 | 0.78 | MAPK14 (0.41) | MAPK14NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL9104044 | 0.78 | MEN1 (0.40) | MAPK14NPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL9108586 | 0.78 | JAK2 (0.40) | DYRK1AMAPK14C1R | |
| SCHEMBL9105551 | 0.76 | MAPK14 (0.41) | MAPK14RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859768-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859768-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859768-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-20120142732-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142732-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142732-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| WO-2012021615-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142732-A1 | HETEROARYLS AND USES THEREOF | PIK3R4, PIK3C2B, PIK3R1 | PIK3C3 52/4885PIM1 1337/4885PIM3 1540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.